Disputas: Johan Caspar Wohlfahrt

M.Sc. Johan Caspar Wohlfahrt ved IKO vil forsvare sin avhandling for graden Ph.d.: On the use of titanium based materials as non-resorbable bone substitutes.

Tid og sted for prøveforelesning

2. februar, 14.15, Store Aud., Geitmyrsveien 69


  • Professor Tord Berglundh, Göteborgs universitet
  • Forsker Andreas Stavropoulos, Aarhus Universitet
  • Professor Alix Young Vik, Universitetet i Oslo

Leder av disputas

Instituttleder Pål Barkvoll



On the use of titanium based materials as non-resorbable bone substitutes

This thesis consist of experimental and clinical work on the use of titanium based bone graft substitutes for reconstruction of bone defects adjacent to implants and teeth.

The thesis includes five papers that present data from two animal experimental studies, one human case with histological analysis and two clinical studies. Two different animal experimental models and two clinical models were used to achieve the specific aims. In paper I, a rabbit tibia defect model including cortical model implants was used, comparing treatment with porous titanium granules (PTG) with sham and heat oxidized PTG in defects proximal to the titanium implants. In paper II, a mini pig furcation defect model was employed, comparing the effect of PTG against sham and deproteinized bovine bone mineral for treatment of surgically created degree II furcation defects. In paper III and IV, the use of PTG as a bone substitute in the surgical treatment of human peri-implant osseous defects was studied. Finally, in paper V, the potential for PTG as a reconstructive biomaterial for use in periodontal furcation defects in human mandibular molars, was investigated. Both the animal experimental and human histological results suggested that PTG is biocompatible and can promote healing of osseous defects and re-osseointegration of dental implants. The clinical results were encouraging, but inconclusive. Further studies, combining the non-resorbable titanium-based biomaterial with other reconstructive therapies such as guided tissue regeneration, or as a carrier for bone growth-promoting molecules, is encouraged.

Publisert 19. jan. 2012 08:27